Relationship of miR-101 and targeted epigenetic silencing of EzH2 on cell growth and invasiveness in ovarian cancer cells.

R. B. Batchu; A. Semaan; S. M. Seward; A. Qazi; S. Chamala; C. S. Bryant; C. Steffes; S. Kumar; M. A. Shammas; D. W. Weaver

doi:10.1200/JCO.2010.28.15_SUPPL.E15538

Relationship of miR-101 and targeted epigenetic silencing of EzH2 on cell growth and invasiveness in ovarian cancer cells.

R. B. Batchu
, A. Semaan
, S. M. Seward
, A. Qazi
, S. Chamala
, C. S. Bryant
, C. Steffes
, S. Kumar
, M. A. Shammas
, D. W. Weaver

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	28
DOIs	https://doi.org/10.1200/JCO.2010.28.15_SUPPL.E15538
State	Published - May 20 2010

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2010.28.15_SUPPL.E15538License: Unspecified

Cite this

@article{4c683cd657644832aad8337e6731ff3f,

title = "Relationship of miR-101 and targeted epigenetic silencing of EzH2 on cell growth and invasiveness in ovarian cancer cells.",

author = "Batchu, \{R. B.\} and A. Semaan and Seward, \{S. M.\} and A. Qazi and S. Chamala and Bryant, \{C. S.\} and C. Steffes and S. Kumar and Shammas, \{M. A.\} and Weaver, \{D. W.\}",

note = "e15538 Background: Enhancer of zeste homolog 2 (EzH2), the catalytic subunit of Polycomb group (PcG) of the chromatin modifying complex, is abnormally elevated in several cancers. High levels of EzH2 correlate strongly with high-grade malignancies that are invasive, poorly differentiated and of advanced stage at presentation.",

year = "2010",

month = may,

day = "20",

doi = "10.1200/JCO.2010.28.15\_SUPPL.E15538",

language = "American English",

volume = "28",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Relationship of miR-101 and targeted epigenetic silencing of EzH2 on cell growth and invasiveness in ovarian cancer cells.

AU - Batchu, R. B.

AU - Semaan, A.

AU - Seward, S. M.

AU - Qazi, A.

AU - Chamala, S.

AU - Bryant, C. S.

AU - Steffes, C.

AU - Kumar, S.

AU - Shammas, M. A.

AU - Weaver, D. W.

N1 - e15538 Background: Enhancer of zeste homolog 2 (EzH2), the catalytic subunit of Polycomb group (PcG) of the chromatin modifying complex, is abnormally elevated in several cancers. High levels of EzH2 correlate strongly with high-grade malignancies that are invasive, poorly differentiated and of advanced stage at presentation.

PY - 2010/5/20

Y1 - 2010/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e15538

U2 - 10.1200/JCO.2010.28.15_SUPPL.E15538

DO - 10.1200/JCO.2010.28.15_SUPPL.E15538

M3 - Article

VL - 28

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Relationship of miR-101 and targeted epigenetic silencing of EzH2 on cell growth and invasiveness in ovarian cancer cells.

Disciplines

Access to Document

Other files and links

Cite this